98%
921
2 minutes
20
Background: Laser immunotherapy is a new anti-cancer therapy combining photothermal therapy and immunostimulation. It can eliminate the tumours by damaging tumour cells directly and promoting the release of damage-associated molecular patterns (DAMPs) to enhance tumour immunogenicity. The aim of this study was to investigate the thermal effects of laser immunotherapy and to evaluate the effectiveness and safety of laser immunotherapy for cutaneous squamous cell carcinoma (cSCC).
Methods: The cell viability and the DAMPs productions of heat-treated cSCC A431 cells in different temperatures were investigated. Laser immunotherapy with the optimal thermal effect for DAMPs production was performed on SKH-1 mice bearing ultraviolet-induced cSCC and a patient suffering from a large refractory cSCC.
Results: The temperature in the range of 45-50 °C killing half of A431 cells had an optimal thermal effect for the productions of DAMPs. The thermal effect could be further enhanced by local application of imiquimod, an immunoadjuvant. Laser immunotherapy eliminated most tumours and improved the survival rate of the ultraviolet-induced cSCC-bearing SKH-1 mice (p < 0.05). The patient with cSCC treated by laser immunotherapy experienced a significant tumour reduction after laser immunotherapy increased the amounts of infiltrating lymphocytes in the tumour. No obviously adverse effect was observed in the mice experiment or in the clinical application.
Conclusions: Our results strongly indicate that laser immunotherapy with optimal thermal effects is an effective and safe treatment modality for cSCC.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6136962 | PMC |
http://dx.doi.org/10.1080/02656736.2018.1446221 | DOI Listing |
J Invest Dermatol
September 2025
Department of Dermatology, CHU Nice, University Côte d'Azur, Nice, France; C3M, INSERM U1065, University Côte d'Azur, Nice, France.
ACS Nano
September 2025
State Key Laboratory of Flexible Electronics (LoFE) & Jiangsu Key Laboratory of Smart Biomaterials and Theranostic Technology, Institute of Advanced Materials (IAM), School of Chemistry and Life Sciences, College of Electronic and Optical Engineering & College of Flexible Electronics (Future Technol
Gynecologic malignancies are prone to metastasis and recurrence due to the low efficacy and sensitivity of current clinical treatments. Here, we construct ultrasmall Sb@Au nanodots (Sb@Au NDs) as a metallothionein 2A (MT 2A)-silencing nanoagonist for effective photothermal immunotherapy of gynecologic malignancies. Sb@Au NDs show high photothermal conversion efficiency of 56.
View Article and Find Full Text PDFAdv Healthc Mater
September 2025
Key Laboratory of Magnetic Molecules and Magnetic Information Materials of Ministry of Education & School of Chemistry and Materials Science of Shanxi Normal University, TaiYuan, 030032, P. R. China.
The photothermal conversion efficiency (PCE) stands as a pivotal determinant in the therapeutic efficacy of photothermal nanoagents (PTNAs) within the context of photothermal therapy (PTT). The dearth of universal strategies to greatly enhance PCE has markedly curtailed the practical deployment of PTNAs. Now this problem is addressed by proposing a universal approach founded on molecular rotors and J-aggregates, "highly efficient molecular motor matrix", to greatly elevate the PCE of traditional PTNAs.
View Article and Find Full Text PDFAdv Healthc Mater
September 2025
Brain Center, Department of Neurosurgery, Zhongnan Hospital of Wuhan University, Ministry of Education Key Laboratory of Combinatorial Biosynthesis and Drug Discovery, School of Pharmaceutical Sciences, Wuhan University, Wuhan, Hubei, 430071, China.
Glioblastoma multiforme (GBM) continues to pose a significant challenge in the field of neuro-oncology primarily because of the limited penetration of therapeutics across the blood-brain barrier (BBB) and the presence of immunosuppressive tumor microenvironments. To address these challenges, a HD-PEG@BM biomimetic nanoplatform (hereinafter referred to as HD-P@BM) is developed that cloaks the near-infrared II photosensitizer HD-PEG (HD-P) inside microglial membranes to enable enhanced BBB penetration and tumor-targeted delivery. In this study, it is found that the microglia-derived membranes enhanced the uptake of nanoparticles by both the glioma cells and tumor-associated microglia.
View Article and Find Full Text PDFPLoS One
August 2025
Section of Virology and Immunotherapy, Department of Neurosurgery, University of Miami Leonard M. Miller School of Medicine, Miami, Florida, United States of America.
This clinical trial is registered on ClinicalTrials.gov (NCT06428045). The authors confirm that all ongoing and related trials for this intervention are registered.
View Article and Find Full Text PDF